BioStem Technologies, Inc. (BSEM)
NASDAQ: BSEM · Real-Time Price · USD
1.680
+0.040 (2.44%)
At close: Oct 21, 2026, 4:00 PM EDT
1.650
-0.030 (-1.79%)
After-hours: Oct 21, 2026, 7:30 PM EDT
BioStem Technologies Revenue
BioStem Technologies had revenue of $7.90M in the quarter ending June 30, 2026, a decrease of -27.95%. This brings the company's total for the last twelve months to $34.59M, down -49.13% year-over-year. In the year 2025, BioStem Technologies had annual revenue of $47.48M, down -31.84%. That makes BioStem Technologies the 30,453rd largest company in the world by revenue and 4,028th in the United States.
Revenue (ttm)
$34.59M
Revenue Growth
-49.13%
P/S Ratio
0.90
Revenue / Employee
$473,789
Employees
73
Market Cap
31.22M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 47.48M | -22.18M | -31.84% |
| Dec 31, 2024 | 69.66M | 52.97M | 317.48% |
| Dec 31, 2023 | 16.69M | 9.81M | 142.69% |
| Dec 31, 2022 | 6.88M | 2.53M | 58.38% |
| Dec 31, 2021 | 4.34M | 4.03M | 1,284.88% |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2011 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aligos Therapeutics | 31.52M |
| Metagenomi Therapeutics | 13.56M |
| Evaxion | 7.49M |
| EyePoint | 2.79M |
| CervoMed | 331.30K |
| Impact BioMedical | 35.00K |
BSEM News
- 19 days ago - BioStem Technologies registers to sell 2.22M shares of common stock for holders - TheFly
- 19 days ago - BioStem Technologies Registration statement: Registration filing - Filings
- 20 days ago - BioStem Technologies announces USPTO issued 1 patent, 3 notices of allowance - TheFly
- 21 days ago - BioStem Technologies prices 735,296 shares at $4.08 in private placement - TheFly
- 4 weeks ago - Terminal1, the operating system built for public companies, announced today that BioStem Technologies, Inc. (NASDAQ: BSEM) has joined the Terminal1 platform - GlobeNewsWire
- 4 weeks ago - BioStem Technologies files to sell 12.05M shares of common stock for holders - TheFly
- 4 weeks ago - BioStem Technologies Registration statement: Registration filing - Filings
- 5 weeks ago - BioStem Technologies Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts